- Home
- MYNZ vs BGLC Comparison
MYNZ vs BGLC Comparison
Compare MYNZ & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- BGLC
- Stock Information
- Founded
- MYNZ 2021
- BGLC 2017
- Country
- MYNZ Germany
- BGLC Malaysia
- Employees
- MYNZ N/A
- BGLC N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- BGLC Medical Specialities
- Sector
- MYNZ Health Care
- BGLC Health Care
- Exchange
- MYNZ Nasdaq
- BGLC Nasdaq
- Market Cap
- MYNZ 7.6M
- BGLC 10.7M
- IPO Year
- MYNZ 2021
- BGLC N/A
- Fundamental
- Price
- MYNZ $1.90
- BGLC $6.10
- Analyst Decision
- MYNZ Buy
- BGLC
- Analyst Count
- MYNZ 2
- BGLC 0
- Target Price
- MYNZ $14.00
- BGLC N/A
- AVG Volume (30 Days)
- MYNZ 186.6K
- BGLC 3.1M
- Earning Date
- MYNZ 08-05-2025
- BGLC 08-13-2025
- Dividend Yield
- MYNZ N/A
- BGLC N/A
- EPS Growth
- MYNZ N/A
- BGLC N/A
- EPS
- MYNZ N/A
- BGLC N/A
- Revenue
- MYNZ $893,991.00
- BGLC $9,265,870.00
- Revenue This Year
- MYNZ $26.06
- BGLC N/A
- Revenue Next Year
- MYNZ $4.97
- BGLC N/A
- P/E Ratio
- MYNZ N/A
- BGLC N/A
- Revenue Growth
- MYNZ N/A
- BGLC N/A
- 52 Week Low
- MYNZ $1.34
- BGLC $2.01
- 52 Week High
- MYNZ $19.00
- BGLC $15.60
- Technical
- Relative Strength Index (RSI)
- MYNZ 49.46
- BGLC 48.48
- Support Level
- MYNZ $1.89
- BGLC $4.73
- Resistance Level
- MYNZ $2.07
- BGLC $5.33
- Average True Range (ATR)
- MYNZ 0.21
- BGLC 0.67
- MACD
- MYNZ 0.02
- BGLC -0.16
- Stochastic Oscillator
- MYNZ 38.10
- BGLC 25.57
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.